Lung cancer continues to be a major global health challenge, representing the leading cause of cancer-related deaths worldwide. Among its subtypes, non-small cell lung cancer (NSCLC) constitutes nearly 85% of cases, encompassing adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Traditional approaches to diagnosis and treatment reli

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  New Gene Therapy Expands Treatment Options for SMA The FDA has approved a new intrathecal gene therapy for spinal muscular atrophy (SMA) in patients aged two years and older with confirmed SMN1 mutations. Delivered directly into the spina

Introduction Elranatamab-BCMM is a humanized bispecific antibody that binds B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting cytotoxic activity against multiple myeloma cells (1). In phase 2 MagnetisMM-3, subcutaneous step-up dosing followed by weekly and then biweekly schedules achieved deep responses with

Introduction: Lung cancer is the leading cause of cancer-related deaths in men and the second most common in women (1). Non-small cell lung cancer (NSCLC) comprises most cases and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma (1). Management is guided by functional status, comorbidities, tumour stage, and molecular char

Introduction Elranatamab-BCMM is a bispecific antibody targeting B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, redirecting immune cytotoxicity to eliminate multiple myeloma cells (1). Its subcutaneous administration and step-up dosing schedule are designed to mitigate cytokine release syndrome (CRS) while allowing o

This insightful conversation with Dr. Manikandan Venkatasubramaniyan explores the fast-changing field of thoracic oncology through a clinical lens. Key highlights include: The shift from standalone surgical management to multidisciplinary, precision-based treatment. How molecular profiling (EGFR, ALK, KRAS) is influencing not only systemic therapy

Introduction Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with high mortality, often exceeding that of malignant melanoma (1). It primarily affects older adults with extensive ultraviolet (UV) exposure or immunosuppression (1). Traditional chemotherapy provides rapid tumor regression but lacks durable survival benefi

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  Novel Bispecific Antibody Shows Major Follicular Lymphoma Benefit The FDA has approved a novel T-cell-engaging bispecific antibody for adults with relapsed or refractory follicular lymphoma, in combination with standard immunotherapy and

Introduction Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine cancer of the skin, primarily caused by ultraviolet (UV) radiation or Merkel cell polyomavirus (MCPyV) infection (1). It most often affects older or immunocompromised individuals and is characterised by rapid progression, early lymphatic spread, and frequent rec